Kyverna Therapeutics Closes $85 Million Series B Financing Led By Northpond Ventures [TheStreet.com]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: TheStreet.com
EMERYVILLE, Calif., Jan. 26, 2022 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. Additional investors included the company's founding investors Westlake Village BioPartners ("Westlake"), Vida Ventures, and Gilead Sciences ("Gilead"), with new investors RTW Investments, LP ("RTW"), CAM Capital, Insight Partners, HealthCor, LYFE Capital, Intellia Therapeutics, Argentum Peak, Hudson Bay Capital, and jVen Capital. Proceeds from the financing will be used to advance KYV-101, an autologous version of a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties uniquely suited for use in B cell-driven autoimmune diseases such as lupus nephritis, systemic sclerosis, and inflammatory myopathies. Kyverna has obtained exclusive, worldwide licenses from
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Notable earnings after Thursday's close [Seeking Alpha]Seeking Alpha
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at HSBC Holdings plc from a "reduce" rating to a "hold" rating. They now have a $69.00 price target on the stock.MarketBeat
- Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? [Seeking Alpha]Seeking Alpha
- Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect? [Yahoo! Finance]Yahoo! Finance
- Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- 3/29/24 - Form 4
- GILD's page on the SEC website